Differential Immunodominance Hierarchy of CD8 + T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection

Author:

Adland Emily1,Hill Matilda1,Lavandier Nora1,Csala Anna1,Edwards Anne2,Chen Fabian3,Radkowski Marek4,Kowalska Justyna D.4,Paraskevis Dimitrios5,Hatzakis Angelos5,Valenzuela-Ponce Humberto6,Pfafferott Katja7,Williams Ian8,Pellegrino Pierre8,Borrow Persephone7,Mori Masahiko1,Rockstroh Jürgen9,Prado Julia G.10,Mothe Beatriz1011,Dalmau Judith10,Martinez-Picado Javier101112,Tudor-Williams Gareth13,Frater John714,Stryhn Anette15,Buus Soren15,Teran Gustavo Reyes6,Mallal Simon16,John Mina17,Buchbinder Susan18,Kirk Gregory19,Martin Jeffrey20,Michael Nelson21,Fellay Jacques22,Deeks Steve18,Walker Bruce23,Avila-Rios Santiago6,Cole David2425,Brander Christian101112,Carrington Mary2326,Goulder Philip1

Affiliation:

1. Department of Paediatrics, University of Oxford, United Kingdom

2. Department of GU Medicine, The Churchill Hospital, Oxford University NHS Foundation Trust, Oxford, United Kingdom

3. Department of Sexual Health, Royal Berkshire Hospital, Reading, United Kingdom

4. Department of Immunopathology of Infectious and Parasitic Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland

5. Medical School, National and Kapodistrian University of Athens, Athens, Greece

6. Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico

7. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

8. Centre for Sexual Health and HIV Research, Mortimer Market Centre, London, United Kingdom

9. Department of Medicine I, University Hospital Bonn, Bonn, Germany

10. AIDS Research Institute IrsiCaixa, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, Badalona, Spain

11. University of Vic-Central University of Catalonia (UVic-UCC), Vic, Barcelona, Spain

12. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

13. Department of Paediatrics, Imperial College, London, United Kingdom

14. Oxford Martin School, University of Oxford, Oxford, United Kingdom

15. Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

16. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

17. Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia

18. San Francisco Department of Public Health, HIV Research Section, San Francisco, California, USA

19. Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, USA

20. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA

21. U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

22. School of Life Sciences, EPFL, Lausanne, Switzerland

23. Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA

24. Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom

25. Immunocore Limited, Abingdon, Oxfordshire, United Kingdom

26. Cancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Maryland, USA

Abstract

ABSTRACT The well-characterized association between HLA-B*27:05 and protection against HIV disease progression has been linked to immunodominant HLA-B*27:05-restricted CD8 + T-cell responses toward the conserved Gag KK10 (residues 263 to 272) and polymerase (Pol) KY9 (residues 901 to 909) epitopes. We studied the impact of the 3 amino acid differences between HLA-B*27:05 and the closely related HLA-B*27:02 on the HIV-specific CD8 + T-cell response hierarchy and on immune control of HIV. Genetic epidemiological data indicate that both HLA-B*27:02 and HLA-B*27:05 are associated with slower disease progression and lower viral loads. The effect of HLA-B*27:02 appeared to be consistently stronger than that of HLA-B*27:05. In contrast to HLA-B*27:05, the immunodominant HIV-specific HLA-B*27:02-restricted CD8 + T-cell response is to a Nef epitope (residues 142 to 150 [VW9]), with Pol KY9 subdominant and Gag KK10 further subdominant. This selection was driven by structural differences in the F pocket, mediated by a polymorphism between these two HLA alleles at position 81. Analysis of autologous virus sequences showed that in HLA-B*27:02-positive subjects, all three of these CD8 + T-cell responses impose selection pressure on the virus, whereas in HLA-B*27:05-positive subjects, there is no Nef VW9-mediated selection pressure. These studies demonstrate that HLA-B*27:02 mediates protection against HIV disease progression that is at least as strong as or stronger than that mediated by HLA-B*27:05. In combination with the protective Gag KK10 and Pol KY9 CD8 + T-cell responses that dominate HIV-specific CD8 + T-cell activity in HLA-B*27:05-positive subjects, a Nef VW9-specific response is additionally present and immunodominant in HLA-B*27:02-positive subjects, mediated through a polymorphism at residue 81 in the F pocket, that contributes to selection pressure against HIV. IMPORTANCE CD8 + T cells play a central role in successful control of HIV infection and have the potential also to mediate the eradication of viral reservoirs of infection. The principal means by which protective HLA class I molecules, such as HLA-B*27:05 and HLA-B*57:01, slow HIV disease progression is believed to be via the particular HIV-specific CD8 + T cell responses restricted by those alleles. We focus here on HLA-B*27:05, one of the best-characterized protective HLA molecules, and the closely related HLA-B*27:02, which differs by only 3 amino acids and which has not been well studied in relation to control of HIV infection. We show that HLA-B*27:02 is also protective against HIV disease progression, but the CD8 + T-cell immunodominance hierarchy of HLA-B*27:02 differs strikingly from that of HLA-B*27:05. These findings indicate that the immunodominant HLA-B*27:02-restricted Nef response adds to protection mediated by the Gag and Pol specificities that dominate anti-HIV CD8 + T-cell activity in HLA-B*27:05-positive subjects.

Funder

Wellcome Trust

Frederick National Laboratory for Cancer Research

HHS | National Institutes of Health

RCUK | Medical Research Council

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3